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Although the highest levels of PPARγ expression in the body have been reported in the gastrointestinal epithelium, little is known
about the physiological functions of that receptor in the gut. Moreover, there is considerable controversy concerning the eﬀects
of thiazolidinedione PPARγ agonists on the two major diseases of the gastrointestinal track: colorectal cancer and inﬂammatory
bowel disease. We will undertake to review both historical and recently published data with a view toward summarizing what is
presently known about the roles of PPARγ in both physiological and pathological processes in the gastrointestinal epithelium.
Copyright © 2008 Brian M. Necela and E. Aubrey Thompson. This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptor-gamma (PPARγ,
NR1C3) has been described as a master regulator of
adipocytes diﬀerentiation [1]; and since the discovery that
the insulin-sensitizing thiazolidinedione drugs are PPARγ
agonists[2],theroleofthisreceptorinadipogenesishasbeen
studiedindetail.PPARγ isalsoabundantinthegastrointesti-
nal tract, where it is highly expressed in epithelial cells [3, 4].
High-level expression of PPARγ in the gut epithelium sug-
gests some important physiological role in the gut, although
this role is not well understood. From the standpoint of
pathology, PPARγ has been implicated in both transfor-
mation and inﬂammation in the gut. However, there are
conﬂicting data concerning the eﬃcacy and even the safety
of PPARγ agonists in clinical management of gastrointestinal
cancer and inﬂammation. We will undertake in this review
to summarize both historical and recent data that relate to
three questions: What is the physiological role of PPARγ
in gastrointestinal epithelial cells? Is PPARγ ac o l o nc a n c e r
suppressor? And what is the role of PPARγ in inﬂammation?
2. THE PHYSIOLOGICAL ROLE OF PPARγ IN
GASTROINTESTINAL EPITHELIAL CELLS
PPARγ is expressed in epithelial cells of both the large and
small intestines [3, 4]. Relatively lower levels of expression
are observed in the small intestine, which appears to
express PPARγ at more or less uniform abundance from the
duodenum to the caecum [5]. Very high levels of PPARγ are
expressed in the proximal colon, with somewhat lower levels
observedinthemidanddistalcolon[5,6].Thehighestlevels
of PPARγ in the body are observed in highly diﬀerentiated
lumenalepithelialcellsoftheproximalcolon.Ithasalsobeen
observed that PPARγ is induced when Caco2 cells undergo
diﬀerentiation in culture [6], leading to the suggestion that
induction of PPARγ is associated with diﬀerentiation of
colonic epithelial cells. However, a careful analysis of PPARγ
expression in the colon suggests that this conclusion is
correct only within a limited context [5]. Basal epithelial
cells of proximal crypts are highly diﬀerentiated, yet express
signiﬁcantly lower levels of PPARγ than lumenal epithelial
cells from the same crypts. Furthermore, PPARγ expression
in the distal colon is more or less uniform throughout the
crypts, with slightly higher levels of expression observed in
the less diﬀerentiated basal crypt cells, rather than the more
highly diﬀerentiated lumenal epithelial cells [5, 7]. Thus, it is
not generally the case that induction of PPARγ is associated
with diﬀerentiation of colonic epithelial cells. It is, however,
the case that all colonic epithelial cells express signiﬁcant
levels of PPARγ. This is an important point, since some of
the eﬀects of PPARγ are manifest in the transit amplifying
cellsthatsupportrenewalofthecolonicepithelium.Whether2 PPAR Research
PPARγ is expressed in colonic stem cells remains an open
question.
A signiﬁcantly diﬀerent pattern of PPARγ expression is
observed in the epithelium of the small intestine. Transit
amplifyingcellswithinthecryptsofLieberk¨ uhnexpresslittle
or no PPARγ [8, 9]. Instead, this receptor is induced at the
crypt/villus junction, where small intestinal epithelial cells
undergo diﬀerentiation into mature villus epithelial cells.
Thus, in the small intestine it is unambiguously the case
that induction of PPARγ is associated with diﬀerentiated
function, and it has been reported that PPARγ collaborates
with Hic5 to promote diﬀerentiation of embryonic small
intestinal epithelial cells [10].
Eﬀorts to understand the role of PPARγ in diﬀerentiated
function of gut epithelial cells have been hindered by the
lack of good cellular models to study the mechanisms of
action of PPARγ in culture. There are no nontransformed
colonic epithelial cell lines, and primary colonic epithelial
c e l l sh a v ep r o v e dt ob ed i ﬃcult, if not impossible, to
maintain in culture for even a few hours. There are several
nontransformed epithelial cell lines derived from the rat
embryonic small bowel (e.g., RIE1 and IEC6), but these
cells are derived from proliferative crypt cells and, like the
transit amplifying cells from which they were derived, these
cells express no PPARγ. It has been possible to engineer
RIE1 cells to express PPARγ, thereby modeling the transition
that occurs at the crypt/villus junction [8, 11]. Activation
of PPARγ in such cells results in irreversible withdrawal
form the cell cycle, promotes motility, and reduces cellular
adhesion.
Genomic proﬁling indicates that PPARγ targets in such
cells fall into four major functional cohorts [8]. The largest
of these cohorts consists of genes that are involved in
metabolism, and a large proportion of lipid transport and
metabolism genes are evidenced within this group. This
observation is consistent with our understanding of the
metabolic role of PPARγ in other tissues [12–16]. A second
cohort of PPARγ target genes was ontologically linked to
signal transduction. The data suggest that there is extensive
crosstalk between PPARγ and other signaling pathways
within intestinal epithelial cells. A third cohort of genes was
linked to proliferation, consistent with the observation that
activation of PPARγ within these cells results in inhibition
of culture growth and irreversible withdrawal from the cell
cycle. Somewhat surprisingly, the forth functional cohort
of PPARγ target genes was ontologically linked to cellular
motility and adhesion. Such processes have not been gener-
ally thought of as linked to activation of nuclear receptors.
Nevertheless,activationofPPARγ inintestinalepithelialcells
potently induces cellular motility, through a mechanism that
involves Rho family GTPases and MAPK activation [11].
Renewal of the intestinal epithelium is tightly coupled to
migration of diﬀerentiated epithelial cells from the crypts
to the villus tips, and the observation that PPARγ regulates
intestinal epithelial cell motility provides a very important
clue into the potential physiological role of this receptor in
the gastrointestinal epithelium.
Genomic analysis of PPARγ targets in colonic epithelial
cells isolated from thiazolidinedione-treated mice indicates
that, in general, similar processes are regulated in epithelial
cells from the colon and small intestine [5]. Major onto-
logical cohorts were identiﬁed that link PPARγ activation
to metabolism, signal transduction, and migration/motility.
In contrast to the results obtained with intestinal epithelial
cells in culture, no proliferative cohort of PPARγ target
genes was identiﬁed in colonic epithelial cells isolated from
thiazolidinedione-treated mice. This result was unantici-
pated since such drugs signiﬁcantly inhibit BrdU incor-
poration into both proximal and distal colonic epithelial
cells. Failure to detect a cohort of proliferation-related
PPARγ target genes in vivo is probably attributable to the
fact that only a small subpopulation of cells is involved
in proliferation in the colonic epithelium, such that the
contribution of RNA from such cells is diluted by the much
larger postmitotic population. Genomic studies of this sort
are, therefore, useful for analysis of PPARγ eﬀect on the
diﬀerentiated, postmitotic epithelial cells; but such studies
are unlikely to reveal much information about the eﬀects
of PPARγ on proliferative colonic epithelial cells, which are
presumably the targets for transformation.
PPARγ expression and distribution are very diﬀerent
in the proximal and distal colonic epithelium, implying
that this receptor may have diﬀerent functions in the
proximal and distal colon. Genomic analysis indicates that
the majority of PPARγ target genes are expressed in both
proximal and distal epithelial cells [5], suggesting that there
is substantial overlap between the physiological functions
of PPARγ in these tissues. However, a subset of PPARγ
target genes is restricted to the proximal colon, and a
second subset is expressed predominantly in the distal colon.
Intriguingly,theproximalPPARγ targetgenesareallinduced
by thiazolidinediones, whereas the distal target genes are all
repressed. The signiﬁcance of this observation is unknown
at this time. However, the observation that PPARγ represses
genes that are diﬀerentially expressed in the distal colon is
consistent with the hypothesis that PPARγ may suppress
diﬀerentiated function in that tissue. This hypothesis tends
to contradict a large number of observations to the eﬀect
that PPARγ promotes diﬀerentiated function, and additional
studiesareneededtoconﬁrmthisunanticipatedobservation.
In summary, the lack of appropriate cellular models to
study the mechanism of action of PPARγ in nontransformed
gut epithelial cells has signiﬁcantly impaired our ability
to understand the role of this receptor in gut physiology.
Nevertheless, genomic analyses of genetically engineered
intestinal epithelial cells and colonic epithelial cells iso-
lated from thiazolidinedione-treated mice have provided
important clues. The data suggest that PPARγ is a potent
metabolic regulator in gut epithelial cells. This suggestion
is obviously consistent with what we know about PPARγ
in mesenchymal cells. There is a strong suggestion that
PPARγ is involved in extensive crosstalk with other signal
transduction pathways, suggesting that this receptor plays an
important role in integrating the physiological response to
a wide variety of extracellular signals in vivo. Finally, both
genomic and cellular data indicate that PPARγ plays a very
important role in regulating cellular motility, which is one
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cells. The challenge at this time is to put the information we
have into a physiological context and to use these data to
understand the role of PPARγ in malignant transformation
of gastrointestinal epithelial cells.
3. PPARγ AS A COLON CANCER SUPPRESSOR
T h ee v i d e n c ei ns u p p o r to fP P A R γ as a colon cancer
suppressor is based upon a relatively small number of
observations, and not all of these observations are con-
sistent with each other. The most compelling data come
from studies using the azoxymethane (AOM)-treated rodent
model, which has been widely studied as a model of sporadic
coloncarcinogenesis.TwoinitialstudiesinAOM-treatedrats
used troglitazone, a relatively weak PPARγ agonist [17, 18].
The endpoint in these experiments was aberrant crypt foci
(ACF), rather than colon tumors. Nevertheless, both of
these studies indicated that troglitazone potently inhibits
ACF formation, thereby presumably reducing the risk of
subsequent tumor formation in rats. It was subsequently
shown that troglitazone, pioglitazone, and rosiglitazone
inhibit ACF formation in AOM-treated Balb/c mice [19].
This was the ﬁrst study that demonstrated that thiazolidine-
diones inhibit colon tumor formation, in addition to ACF
formation, in the AOM model of colon carcinogenesis. This
observationwasconsistentwiththereportthatwholeanimal
hemizygous knockout of PPARγ suppressed AOM-mediated
c o l o nt u m o rf o r m a t i o ni nm i c e[ 7]. It has subsequently been
reported that RS5444, a very high-aﬃnity third generation
thiazolidinedione, inhibits ACF formation and blocks tumor
formation in AOM-treated C57BL/6 mice [5, 20]. Overall,
thesedataunambiguouslyindicate thatPPARγ inhibits some
very early step in transformation of colonic epithelial cells in
AOM-treated rodents.
In contrast to the data cited above, two reports have
concluded that thiazolidinediones induce caecal tumors in
mice [21, 22]. These reports have not been independently
conﬁrmed,andotherinvestigatorshavenotobservedsuchan
eﬀect. However, this may reﬂect the fact that caecal tumors
were observed only in mice that had received very high
concentrations of thiazolidinediones for very long periods
of time [21, 22]. The pathological signiﬁcance of these
observations is unclear at this time. Caecal tumors are very
rare in both mice and humans, and the concentrations of
thiazolidinediones that were used in these experiments were
very likely far beyond any dose that would be tolerated in
humans, in which peripheral edema is the dose limiting
response to such drugs. Nevertheless, the potential signiﬁ-
cance of these disturbing observations warrants additional
consideration.
The major controversy in the PPARγ ﬁeld has revolved
aroundtwohigh-proﬁlepapersthatreportedincreasedcolon
tumorformationinAPC+/Min micetreatedwiththiazolidine-
diones [23, 24]. One of these papers reported a signiﬁcant
increase in colon tumor size in APC+/Min mice treated with
either troglitazone or rosiglitazone. The companion paper
reported a slight, but signiﬁcant, increase in the number of
colon tumors in APC+/Min mice treated withtroglitazone. No
increase in tumor size was observed in the second report,
which was, therefore, not entirely consistent with the ﬁrst.
Moreover, two subsequent reports failed to reproduce the
eﬀect of thiazolidinediones in APC+/Δ1309 or APC+/Min mice
[25, 26]. It was also reported that whole animal hemizygous
knockoutofPPARγ hadnoaﬀectontumornumberorsizein
APC+/Min mice[7],anobservationthatisatvariancewiththe
notion that PPARγ promotes tumor formation in mice that
contain activating germ line mutations in the Wnt/APC/β-
catenin pathway. It has recently been reported that biallelic
knockout of PPARγ in colonic epithelial cells promotes
tumor formation in APC+/Min mice [27], indicating that
PPARγ is, in fact, acting to suppress tumor formation in the
Min mouse. On the whole, the evidence no longer supports
the hypothesis that activation of PPARγ promotes tumor
formation in mice with germ line APC mutations.
A recent report describes the eﬀects of PPARγ agonists
in pre-established tumors in AOM-treated mice [20]. Such
tumors invariably contain somatic mutations that activate
the Wnt/APC/β-catenin signaling pathway [28]. Thiazo-
linedinediones had no eﬀect on growth or incidence of colon
tumors when the drug was given after tumor formation had
occurred [20]. However, activation of PPARγ under these
circumstances had a profound inhibitory eﬀect on tumor
progression. This eﬀect was most strikingly apparent in the
development of carcinoma in situ, which was detected in
about 1/3 of the control tumors but was never observed in
thiazolidinedione-treated tumors. Since formation of carci-
noma in situ involves invasion of the surrounding stoma,
it is tempting to speculate that this observation indicates
that PPARγ inhibits invasion in vivo, consistent with several
reports that indicate that invasion by human colon cancer
cell lines in culture is inhibited by PPARγ [9, 29]. Notably,
activation of PPARγ in pre-established tumors had no
signiﬁcant eﬀect on BrdU incorporation, consistent with the
lack of any signiﬁcant eﬀect on tumor size. This observation
is at variance with several reports that thiazolidinediones
inhibit proliferation of human colon cancer cell lines in
culture and in xenografts [9, 29–35]. The signiﬁcance of this
discrepancy requires additional investigation, but the data
are consistent with the hypothesis that the suppressive eﬀects
of PPARγ on established tumors may be due to inhibition of
tumor progression, rather than inhibition of tumor growth.
On balance, the data seem unambiguously clear in one
respect: PPARγ suppresses colon carcinogenesis in mice. The
primary eﬀect appears to be inhibition of some early stage
in transformation. The ability of PPARγ to block early stage
transformation is presumably due to some eﬀect on normal
colonic epithelial cells, which emphasizes the importance of
understanding the functions of this receptor in the normal
colonic epithelium. It is also clear that whereas PPARγ
inhibits proliferation of normal intestinal epithelial cells, this
response is attenuated early in transformation. Although the
antiproliferative eﬀects of PPARγ appear to be lost in cells
that have either germ line or somatic mutations in β-catenin
signaling, the data indicate that this receptor still retains
the ability to inhibit tumor progression, at least in AOM-
induced tumors. Finally, we submit that there is very little
solid evidence that PPARγ promotes colon carcinogenesis
under any pharmacologically relevant conditions.4 PPAR Research
The role of PPARγ as a suppressor of colon carcino-
genesis in rodents is beyond question, but the evidence
that PPARγ is a colon cancer suppressor in humans is
not so compelling. Although an early report indicated
that loss-of-function mutations in PPARγ were common
in colon cancer [36], this claim has not subsequently been
conﬁrmed [37]. It has been reported that a polymorphism
in codon 12 of PPARγ is associated with colon cancer risk
[38]. However, this polymorphism is manifest in PPARγ2,
which is expressed at relatively low levels in the colonic
epithelium [3, 4], and not in the major colonic PPARγ
isoform, PPARγ1w h i c hd i ﬀers in N-terminal sequence from
PPARγ2. PPARγ expression is reduced in ulcerative colitis
[39]a n da c r o m e g a l y[ 40], two conditions that predispose
to colon cancer; and one might extrapolate from data
with hemizygous knockout mice [41] to postulate that a
r e d u c t i o ni nP P A R γ expression increases the likelihood of
transformation in the human colon. However, the evidence
in support of such a conclusion is not very strong. Finally, a
small phase II trial in which troglitazone was used to treat
patients with late stage metastatic colon cancer produced
no objective response [42]. One might argue that lack of
response in this case was due to the rather low potency of
the agonist or the very advanced stage of cancer in these
patients. Alternatively, one might point to the data in mice,
which indicate that PPARγ has little or no eﬀect on growth
of established colon tumors in AOM-treated mice [20].
The best evidence for a tumor suppressive role of PPARγ
in humans comes from studies of established human colon
cancer cell lines [9, 29–31, 33–35, 43]. Some of these cells
exhibit growth arrest in culture when treated with thiazo-
lidinediones, and growth of colon cancer xenografts has also
been observed in thiazolidinedione-treated mice. However,
many (in our experience most) human colon cancer cell
lines are resistant to growth inhibition by concentrations of
thiazolidinediones that are suﬃcient to maximally activate
PPARγ. Such observations raise two important questions:
why are some colon cancer cell lines resistant to PPARγ ago-
nists? And to what extent are the eﬀects of thiazolidinediones
dependent upon PPARγ expression and/or activity? Both of
these questions are signiﬁcant in terms of the use of thiazo-
lidinediones as chemotherapeutic agents in colon cancer.
The most compelling case for pharmacological applica-
tion of PPARγ agonists in colon cancer is as a preventive
agent. Clearly, PPARγ is preventive in mouse models of
sporadic colon cancer. However, the legal climate in USA at
thistimedoesnotfavorthedevelopmentofchemopreventive
drugs, particularly those that may have cardiovascular side
eﬀects [44]. These considerations do not preclude a prophy-
lactic use for PPARγ agonists. Patients with large numbers
of ACF are at increased risk for development of subsequent
colon cancers [45–47], and it is plausible that short-term
treatment with PPARγ agonists might result in a decrease in
ACFs and a subsequent reduction in colon cancer risk. From
a clinical standpoint, it is therefore important to ascertain if
activation of PPARγ in humans suppresses ACF formation,
as has been observed in AOM-treated mice.
Finally, it is the case that several million individuals
are taking thiazolidinediones for management of type II
diabetes. It would seem that an epidemiological analysis of
theseindividualsmight,onceandforall,determineifPPARγ
agonists have chemopreventive eﬃcacy. Our initial attempts
to collect data on time to formation of a second polyp
in patients who are taking thiazolidinediones indicates that
there are great many confounding variables, which limit the
power of such an analysis and may account for the fact that
few comprehensive anaylses of the eﬀects of PPARγ agonists
on colon cancer incidence have been reported [48].
In summary, we conclude that both genetic and phar-
macological data indicate that PPARγ suppresses some
early stage in transformation of colonic epithelial cells. We
submit that the balance of evidence is inconsistent with
the hypothesis that PPARγ promotes colon carcinogenesis
under any circumstances. Although it is unlikely that PPARγ
agonists will ever be developed as chemopreventive agents,
it is plausible that we may, by studying the mechanism of
action of PPARγ, elucidate downstream eﬀectors that may
be chemopreventive targets. Furthermore, it is possible that
PPARγ agonists may have clinical applicability in prophylac-
tic management of individuals who are at increased risk of
colon cancer due to large numbers of ACFs.
4. PPARγ AND INFLAMMATORY BOWEL DISEASE
PPARγ has become a potential pharmacological target for
treatment of inﬂammatory diseases of the colon, particularly
ulcerative colitis (UC). PPARγ is highly expressed in both
colonic epithelial cells and macrophages critical for innate
immunity and gut homeostasis. Over the past decade, in
vitroand in vivo studies have deﬁned an anti-inﬂammatory
role for macrophage and epithelial PPARγ in regulating
colonic inﬂammation. Studies utilizing in vitro cell culture
models have established that thiazolidinedione PPARγ ago-
nists can reduce NFκB activation and inﬂammatory gene
expression in colonic epithelial cells [49, 50], macrophages
[51–54], dendritic cells [55–58], and T-cells [59, 60]. How-
ever, the magnitude by which thiazolidinediones reduce
inﬂammatory gene expression and act directly through
PPARγ has been confusing. The anti-inﬂammatory eﬀects
of thiazolidinediones vary among studies due to diﬀerences
in cell models, the concentration, duration, and type of
thiazolidinedione (rosiglitazone, pioglitazone) used, as well
as the context of inﬂammation studied (i.e., inducing agent-
LPS,TNF-α,etc.[61]).Moreimportantly,thiazolidinediones
can reduce inﬂammation in both a PPARγ dependent and
independent manner, with the latter resulting from the use
of high concentrations [62, 63]. Despite confusion, it has
been generally accepted that thiazolidinediones can reduce
inﬂammatory gene expression via PPARγ in epithelial and
immune cells when used at appropriate concentrations.
Perhaps the strongest evidence for an anti-inﬂammatory
role of PPARγ comes from landmark studies indicating
that heterozygous PPARγ deﬁcient mice were more sus-
ceptible to DSS- and TNBS-induced colitis [64, 65]. DSS-
inducedcolitis,inparticular,isanacuteinﬂammationmodel
primarily driven by epithelial disruption and macrophage
inﬁltration. This data indicates that PPARγ expression in
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role. Recent studies elaborated on these ﬁndings by showing
t h a tm i c ed e ﬁ c i e n ti nP P A R γ expression in epithelial cells
and macrophages displayed increased proinﬂammatory gene
expression and susceptibility to DSS colitis [66, 67]. These
ﬁndings suggest that PPARγ expression in at least two cell
types, epithelial and macrophage, can protect against at
least one model of acute colitis (DSS). Questions remain
regarding the importance of macrophage and epithelial
PPARγ in other models of acute and chronic colitis. For
example, what is the role of macrophage or epithelial PPARγ
in a chronic colitis model driven by T-cells? Likewise, little
is known about the role of dendritic and T-cell speciﬁc
expression of PPARγ in colitis, as PPARγ knockout animals
currently do not exist for these cell types. Experimental
models of colitis can be initiated by distinct mechanisms and
driven by inﬁltration of diﬀerent cell types, both epithelial
and immune [68–70]. Given that no single model accurately
mimics human colitis, much remains to be understood
regarding the tissue speciﬁc importance of PPARγ in con-
trolling gut inﬂammation. Furthermore, the importance of
tissue speciﬁc PPARγ expression may depend largely on
the model of colitis examined, emphasizing the need to
utilize multiple models to accurately represent manifesta-
tions of human colitis. Collectively, knockout animals have
conﬁrmed a potential protective role of PPARγ in colitis
but additional research is still required to understand fully
how tissue speciﬁc PPARγ expression inﬂuences diﬀerent
manifestations of colonic inﬂammation.
Based on the evidence that (a) thiazolidinediones can
suppress inﬂammatory gene expression in vitro and (b)
PPARγ expression protects against the development of colitis
in several animal models, it seems logical that PPARγ might
beagoodtargetfortreatmentofgutinﬂammation.Inreality,
the preventative and therapeutic eﬃcacy of targeting PPARγ
with thiazolidinediones for treatment of colitis is debatable.
It remains unclear what phase, if any, would be best for
targeting PPARγ with thiazolidinediones for treatment of
colitis: during the initiation, low grade, moderate, high
grade,orremissionphasesofcolitis.Ourknowledgeislargely
based on animal studies in which acute preventive doses of
thiazolidinediones were administered before the initiation
of colitis. When given acutely (0–3 days) before inducing
stimuli (i.e., DSS or TNBS) [50, 64–67, 71–73] or in the
early life stages of animals that develop spontaneous cancer
(IL-10
−/− mice) [74], thiazolidinediones provide beneﬁcial
eﬀects in the amelioration of inﬂammation. These data
indicatethatatleastonemodeofPPARγ actionistosuppress
the initiation of colitis, and suggest that thiazolidinediones
may be a useful chemopreventative agent for the treatment
of colitis. However, given their potential cardiovascular
side eﬀects, it is unlikely that thiazolidinediones would be
approved as a chronic preventive agent for the management
of gut inﬂammation. Moreover, the eﬀectiveness of long
term-preventative thiazolidinedione treatment on suppress-
ing gut inﬂammation remains to be fully established. A
recentreportindicatesthatlong-termtreatmentofmicewith
rosiglitazone exacerbated DSS-induced colitis [75], raising
concerns about the preventative use of thiazolidinediones in
gut inﬂammation.
The alternative scenario is that thiazolidinediones alone
or in combination with anti-inﬂammatory/immunosupp-
ressive drugs may be used to therapeutically target active
inﬂammation. However, data from human and animal
studies regarding the usefulness of therapeutic doses of
thiazolidinedionesinthetreatmentofcolitisareinconsistent.
When given after the initiation of DSS colitis, several studies
found that thiazolidinediones had little or no value in
improving colitis symptoms [50, 65, 73]. Likewise, ther-
apeutic doses of thiazolidinediones given after established
inﬂammation in the IL-10
−/− model of colitis provided no
value [74]. Similar results were observed in a small open end
clinical trial in which patients with moderate colitis receiving
rosiglitazone experienced only modest improvement [76],
howeverinterpretationoftheseresultsarediﬃcultasthetrial
lacked a proper control group. In contrast, a few studies have
reported that therapeutic doses of rosiglitazone improved
colitis symptoms in DSS and TNBS colitis [64, 77, 78].
Recently, a multicenter, randomized, double blind placebo-
controlled trial for treatment of mild to moderately active
UC with rosiglitazone showed clinical response in 44% of
patients [79]. However, endoscopic remission rates were not
signiﬁcantlydiﬀerent.Thediscrepanciesinthiazolidinedione
eﬀectiveness may reside with the doses of thiazolidinediones
administered, with the magnitude of inﬂammation at the
time of thiazolidinedione administration, or diﬀerences
in scoring. Alternatively, the anti-inﬂammatory actions of
thiazolidinediones may be inhibited or not strong enough
to suppress inﬂammation during active colitis. Most likely,
however, the lack of therapeutic eﬃcacy of thiazolidine-
diones during active colitis can be explained by a loss of
PPARγ expression and/or activity that coincides with the
levelofinﬂammation.Indeed,PPARγ levelshavebeenshown
to be downregulated in epithelial cells [39] and macrophages
[73] during colitis. Moreover, Katayama et al. showed that
the lack of therapeutic responsiveness to thiazolidinediones
during colitis could be restored by adenoviral-mediated
reexpression of PPARγ in the colon [73]. In addition, Necela
et al. showed that NFκBd r i v e sd o w nP P A R γ expression
in response to lipopolysaccharide, thereby obviating the
actions of PPARγ and promoting an inﬂammatory state in
macrophages [80].
In summary, although the current data supports a
role for PPARγ expression and activation in epithelial and
immune cell types in the control of colonic inﬂammation,
it remains unclear whether targeting PPARγ with thiazo-
lidinediones will be an eﬀective strategy for treating gut
inﬂammation. While animal models suggest a favorable role
of thiazolidinediones in chemoprevention, the eﬃcacy and
safety of long-term use of thiazolidinediones as preventative
agents or maintenance therapy in UC patients remains
to be assessed. Likewise, the use of thiazolidinediones as
therapeutic agents for treatment of colitis is controversial. It
remains unclear during what clinical phase of inﬂammation
thiazolidinediones would be most eﬀective for treating UC
patients or which patients would be most likely to beneﬁt
from treatment. Moreover, there is considerable concern
regarding whether the adverse eﬀects of thiazolidinediones
would outweigh the potential beneﬁt for patients with UC.6 PPAR Research
In general, the majority of studies are in agreement that
thiazolidinediones may be better exploited for therapeutic
treatment of mild-moderate active colitis rather than during
severe inﬂammation. Our understanding of the preventative
and therapeutic potential of targeting PPARγ with thiazo-
lidinediones is largely limited by several factors, including
the lack of (a) experimental usage of distinct models of
colitis, (b) understanding of tissue speciﬁc roles of PPARγ in
diﬀerent models of colonic inﬂammation, (c) understanding
of factors aﬀecting thiazolidinedione eﬃcacy (PPARγ levels,
etc.), (d) understanding of the mechanism of the anti-
inﬂammatory actions of PPARγ, and (e) understanding
of the adverse eﬀects of short- and long-term use of
thiazolidinediones during inﬂammation. Additional animal
and clinical studies should resolve these discrepancies and
provide further insight into the appropriate use, preventative
or therapeutic, of thiazolidinediones for treatment of gut
inﬂammation.
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